Results of a study investigating venetoclax combined with ibrutinib for treatment of relapsed chronic lymphocytic leukemia.
Home / Resource Library / MRD-guided venetoclax plus ibrutinib for R/R CLL: results from the phase II HOVON141/VISION trial